A Phase I/II Study of Sunitinib and Dacarbazine

NCT00496223

Last updated date
Study Location
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically documented Stage IV or unresectable Stage III melanoma

- Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to NCI CTCAE Version 3.0 grade less than or equal to 1

- Adequate organ function as defined by the following criteria:

1. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) less than or equal to 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy

2. Total serum bilirubin less than or equal to 1.5 x ULN

3. Absolute neutrophil count (ANC) greater than or equal to 1500/mcL

4. Platelets greater than or equal to 100,000/mcL

5. Hemoglobin greater than or equal to 9.0 g/dL

6. Serum calcium less than or equal to 12.0 mg/dL

7. Serum creatinine less than or equal to 1.5 x ULN

- Patients with CNS metastasis must have had either:

1. Resected CNS metastasis without evidence of recurrence for >12 weeks

2. Brain metastasis treated by stereotactic radiosurgery without evidence of recurrence or progression for 12 weeks

3. Multiple brain lesions treated with WBRT with stable disease off corticosteroids for at least 12 weeks prior to start of therapy

4. Without any evidence of leptomeningeal disease

5. Patients must be neurologically intact

- May have previous adjuvant therapy with interferon, vaccines or therapy with IL-2 or GM-CSF

- Measurable disease by RECIST criteria

- In the phase I part of the trial patients with evaluable but not measurable disease may be allowed with the permission of the PI

- ECOG PS 0-2

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Major surgery or radiation therapy within 4 weeks of starting the study treatment.


- NCI CTCAE grade 3 hemorrhage within 4 weeks of starting the study treatment.


- History of or known carcinomatous meningitis, or evidence of symptomatic
leptomeningeal disease on screening CT or MRI scan.


- Any of the following within the 6 months prior to study drug administration:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident or transient
ischemic attack, or pulmonary embolism.


- Ongoing cardiac dysrhythmias of NCI CTCAE grade greater than or equal to 2.


- QTc >470 msec on baseline EKG.


- History of active CHF or LVEF<50% at screening echocardiogram.


- Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal
medical therapy).


- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication.


- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness or other active infection.


- Concurrent treatment on another clinical trial. Supportive care trials or
non-treatment trials, e.g. QOL, are allowed.


- Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg po
daily for thromboembolism prophylaxis is allowed).


- Pregnancy or breastfeeding. Female subjects must be surgically sterile or be
postmenopausal, or must agree to use effective contraception during the period of
therapy. All female subjects with reproductive potential must have a negative
pregnancy test (serum or urine) prior to enrollment. Male subjects must be surgically
sterile or must agree to use effective contraception during the period of therapy. The
definition of effective contraception will be based on the judgment of the principal
investigator or a designated associate.


- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or may interfere with the interpretation of study results, and in
the judgment of the investigator would make the subject inappropriate for entry into
this study.


- Patients may not have had previous treatment with a DTIC or temozolomide based
chemotherapy regimen. In the Phase II part of the trial patients may not have had
treatment with any chemotherapy regimen.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MelanomaStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Orange County, California
  8. Orange, California
  9. Orange, California
  10. Aurora, Colorado
  11. Boulder, Colorado
  12. Colorado Springs, Colorado
  13. Denver, Colorado
  14. Lakewood, Colorado
  15. Parker, Colorado
  16. Pueblo, Colorado
  17. Chicago, Illinois
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Goshen, Indiana
  22. Goshen, Indiana
  23. Grand Rapids, Michigan
  24. Grand Rapids, Michigan
  25. Grand Rapids, Michigan
  26. Jackson, Mississippi
  27. Jackson, Mississippi
  28. Hackensack, New Jersey
  29. Rochester, New York
  30. Dallas, Texas
  31. Burlington, Vermont
  32. Burlington, Vermont
  33. Burlington, Vermont
  34. Alexandria, Virginia
  35. Arlington, Virginia
  36. Fairfax, Virginia
  37. Fairfax, Virginia
  38. Fairfax, Virginia
  39. Falls Church, Virginia
  40. Gainesville, Virginia
  41. Leesburg, Virginia
  42. Woodbridge, Virginia
  43. Wenatchee, Washington
  44. Caba, Buenos Aires
  45. Buenos Aires, Ciudad Autónoma DE Buenosaires
  46. Buenos Aires, Ciudad Autónoma DE Buenosaires
  47. Buenos Aires, Ciudad Autónoma DE Buenosaires
  48. Buenos Aires, Ciudad Autónoma DE Buenosaires
  49. Buenos Aires, Ciudad Autónoma DE Buenosaires
  50. Buenos Aires, Ciudad Autónoma DE Buenosaires
  51. Gateshead, New South Wales
  52. Southport, Queensland
  53. Southport, Queensland
  54. Southport, Queensland
  55. Woolloongabba, Queensland
  56. Prahran, Victoria
  57. Nedlands, Western Australia
  58. Recife, Pernambuco
  59. Ijuí, RIO Grande DO SUL
  60. Porto Alegre, RIO Grande DO SUL
  61. Barretos, SAO Paulo
  62. Natal,
  63. Rio de Janeiro,
  64. Sao Paulo,
  65. Calgary, Alberta
  66. Toronto, Ontario
  67. Toronto, Ontario
  68. Toronto, Ontario
  69. Montreal, Quebec
  70. Montreal, Quebec
  71. Montreal, Quebec
  72. Montreal, Quebec
  73. Québec, Quebec
  74. Bogotá, Distrito Capital DE Bogotá
  75. Bogotá, Pbx (57-1)
  76. Brno, Jihomoravský KRAJ
  77. Praha 10, Praha, Hlavní Mesto
  78. Praha 2, Praha, Hlavní Mesto
  79. Brno,
  80. Olomouc,
  81. Ostrava Poruba,
  82. Praha,
  83. Nice, Alpes-maritimes
  84. Bordeaux, Gironde
  85. Grenoble, Isère
  86. Reims, Marne
  87. Lille, Nord
  88. Lyon, Rhone
  89. Lyon, Rhône
  90. Le Mans, Sarthe
  91. Villejuif, Val-de-marne
  92. Boulogne-Billancourt,
  93. Lille,
  94. Lyon,
  95. Nice,
  96. Paris,
  97. Paris,
  98. Paris,
  99. Paris,
  100. Pierre-bénite,
  101. Strasbourg,
  102. Templemars,
  103. Villejuif,
  104. Freiburg im Breisgau, Baden-württemberg
  105. Heidelberg, Baden-württemberg
  106. Mannheim, Baden-württemberg
  107. Tübingen, Baden-württemberg
  108. Ulm, Baden-württemberg
  109. München, Bayern
  110. Regensburg, Bayern
  111. Regensburg, Bayern
  112. Würzburg, Bayern
  113. Frankfurt, Hessen
  114. Kassel, Hessen
  115. Kassel, Hessen
  116. Buxtehude, Niedersachsen
  117. Buxtehude, Niedersachsen
  118. Bonn, Nordrhein-westfalen
  119. Minden, Nordrhein-westfalen
  120. Minden, Nordrhein-westfalen
  121. Mainz, Rheinland-pfalz
  122. Magdeburg, Sachsen-anhalt
  123. Dresden, Sachsen
  124. Leipzig, Sachsen
  125. Berlin, Schleswig-holstein
  126. Luebeck, Schleswig-holstein
  127. Lübeck, Schleswig-holstein
  128. Berlin,
  129. Bonn,
  130. Bonn,
  131. Dresden,
  132. Dresden,
  133. Erfurt,
  134. Erfurt,
  135. Essen,
  136. Freiburg,
  137. Gera,
  138. Gera,
  139. Gera,
  140. Hamburg,
  141. Hannover,
  142. Hannover,
  143. Hannover,
  144. Heidelberg,
  145. Homburg,
  146. Kiel,
  147. Lübeck,
  148. Magdeburg,
  149. Magdeburg,
  150. Mainz,
  151. Mannheim,
  152. Minden,
  153. Münster,
  154. Nürnberg,
  155. Regensburg,
  156. Tübingen,
  157. Ulm,
  158. Ulm,
  159. Athens, Attiki
  160. Athens,
  161. Athens,
  162. Piraeus,
  163. Budapest,
  164. Budapest,
  165. Debrecen,
  166. Szolnok,
  167. Ramat Gan, Tel-aviv
  168. Haifa,
  169. Jerusalem,
  170. Torrette Site, Ancona
  171. Napoli, Campania
  172. Roma, Lazio
  173. Roma, Lazio
  174. Lecco, Lombardia
  175. Milan, Lombardia
  176. Monza, Lombardia
  177. Rozzano, Lombardia
  178. Rozzano, Lombardia
  179. Candiolo, Torino
  180. Pisa, Toscana
  181. Terni, Umbria
  182. Padua, Veneto
  183. Bari,
  184. Bergamo,
  185. Bologna,
  186. Genoa,
  187. Milano,
  188. Napoli,
  189. Padova,
  190. Pavia,
  191. Ragusa,
  192. Siena,
  193. Torino,
  194. Fukuoka-shi, Fukuoka
  195. Matsumoto, Nagano
  196. Chuo-ku, Tokyo
  197. Niigata,
  198. Osaka, Ôsaka
  199. Gangnam-Gu, Seoul Teugbyeolsi
  200. Songpa-Gu, Seoul Teugbyeolsi
  201. Seoul,
  202. Seoul,
  203. Seoul,
  204. Seoul,
  205. Mexico,
  206. Mexico,
  207. Nijmegen, Gelderland
  208. Heerlen, Limburg
  209. Amsterdam, Noord Holland
  210. Breda, Noord-brabant
  211. Eindhoven, Noord-brabant
  212. Veldhoven, Noord-brabant
  213. Zwolle, Overijssel
  214. Enschede,
  215. Groningen,
  216. Leiden,
  217. Maastricht,
  218. Rotterdam,
  219. Rotterdam,
  220. Sittard-Geleen,
  221. Oslo,
  222. Oslo,
  223. Oslo,
  224. Warsaw, Mazowieckie
  225. Warszawa, Mazowieckie
  226. Warszawa,
  227. Lisbon, Lisboa
  228. Porto, Proto
  229. Almada,
  230. Lisboa,
  231. Lisboa,
  232. Lisboa,
  233. Porto,
  234. Moscow,
  235. St. Petersburg,
  236. Singapore,
  237. Singapore,
  238. Singapore,
  239. Bratislava,
  240. Bratislava,
  241. Bratislava,
  242. Poprad,
  243. Pretoria,
  244. Pretoria,
  245. Jerez De La Frontera, Andalucía
  246. Oviedo, Asturias
  247. Barcelona, Cataluña
  248. El Palmar, Murcia
  249. Pamplona, Navarra
  250. Pamplona, Navarra
  251. Alicante,
  252. Badalona,
  253. Barcelona,
  254. Barcelona,
  255. Barcelona,
  256. Barcelona,
  257. Donostia-san Sebastián,
  258. Dos Hermanas,
  259. Granada,
  260. La Coruna,
  261. Lleida,
  262. Lleida,
  263. Madrid,
  264. Madrid,
  265. Madrid,
  266. Madrid,
  267. Majadahonda,
  268. Malaga,
  269. Sevilla,
  270. Sevilla,
  271. Sevilla,
  272. Valencia,
  273. Göteborg,
  274. Lund,
  275. Solna,
  276. Uppsala,
  277. Zurich, Zürich (DE)
  278. Bern,
  279. Zürich,
  280. Zürich,
  281. Zürich,
  282. Bornova,
  283. Izmir,
  284. Izmir,
  285. Cambridge, Cambridgeshire
  286. Preston, Lancashire
  287. London, London, CITY OF
  288. Guildford, Surrey
  289. Bebington, Wirral
  290. Sheffield, York
  291. Broomfield,
  292. Leeds,
  293. London,
  294. Manchester,
  295. Oxford,
  296. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
NCT03159117
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPhase I Oncovir Poly IC:LC and NY-ESO-1/gp100
NCT01008527
  1. Tampa, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase I/II Study of Sunitinib and Dacarbazine
Official Title  ICMJE A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma
Brief Summary This is a combination Phase I/II design that explores the toxicity and activity of Sunitinib and Dacarbazine (DTIC) for metastatic melanoma. The initial Phase I part of this trial will consist of a dose escalation of sunitinib while keeping the DTIC dose constant. If no DLT is seen, this dose will be the suggested Phase II trial dose. If less than 2 disease responses are seen, patients will not be enrolled any further, and the study will be considered negative for activity. If a clinical response is seen, patients will continue to be enrolled.
Detailed Description

This is a combination Phase I/II design that explores the toxicity and activity of a combination of sunitinib and Dacarbazine (DTIC) for metastatic melanoma. Screening tests (pre-study) will consist of a history, physical, CBC, CMP, EKG, pregnancy test for women of childbearing age, amylase (blood test for diagnoses of pancreatitis or other pancreatic diseases), staging CT, and PK. Also, on day 1, these tests will be repeated - a history, physical, toxicity assessment, CBC, and amylase test. Re-staging tests will be performed after 2 complete cycles and follow up as indicated clinically.

The initial Phase I part of this trial will consist of a dose escalation of sunitinib while keeping the DTIC dose constant. Sunitinib will be given 2 weeks on and 1 week off with DTIC given once every 21 days for one cycle. If no DLT is seen, the maximum tolerated sunitinib dose will be the suggested as the Phase II trial dose.

Tumor response will be measured after 2 complete cycles. Subsequently, during Phase II the trial will enroll more patients; if less than 2 responses are seen, patients will not be enrolled any further, and the study will be considered negative for activity. But, if a clinical response is seen, more patients will be enrolled at the Phase II dose.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE
  • Drug: Sunitinib
    Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
  • Drug: Dacarbazine
    Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
    Other Name: DTIC
Study Arms  ICMJE Experimental: 1
Interventions:
  • Drug: Sunitinib
  • Drug: Dacarbazine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 28, 2009)
11
Original Estimated Enrollment  ICMJE
 (submitted: July 3, 2007)
53
Actual Study Completion Date  ICMJE June 2007
Actual Primary Completion Date June 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically or cytologically documented Stage IV or unresectable Stage III melanoma
  • Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to NCI CTCAE Version 3.0 grade less than or equal to 1
  • Adequate organ function as defined by the following criteria:

    1. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) less than or equal to 2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy
    2. Total serum bilirubin less than or equal to 1.5 x ULN
    3. Absolute neutrophil count (ANC) greater than or equal to 1500/mcL
    4. Platelets greater than or equal to 100,000/mcL
    5. Hemoglobin greater than or equal to 9.0 g/dL
    6. Serum calcium less than or equal to 12.0 mg/dL
    7. Serum creatinine less than or equal to 1.5 x ULN
  • Patients with CNS metastasis must have had either:

    1. Resected CNS metastasis without evidence of recurrence for >12 weeks
    2. Brain metastasis treated by stereotactic radiosurgery without evidence of recurrence or progression for 12 weeks
    3. Multiple brain lesions treated with WBRT with stable disease off corticosteroids for at least 12 weeks prior to start of therapy
    4. Without any evidence of leptomeningeal disease
    5. Patients must be neurologically intact
  • May have previous adjuvant therapy with interferon, vaccines or therapy with IL-2 or GM-CSF
  • Measurable disease by RECIST criteria
  • In the phase I part of the trial patients with evaluable but not measurable disease may be allowed with the permission of the PI
  • ECOG PS 0-2

Exclusion Criteria:

  • Major surgery or radiation therapy within 4 weeks of starting the study treatment.
  • NCI CTCAE grade 3 hemorrhage within 4 weeks of starting the study treatment.
  • History of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease on screening CT or MRI scan.
  • Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
  • Ongoing cardiac dysrhythmias of NCI CTCAE grade greater than or equal to 2.
  • QTc >470 msec on baseline EKG.
  • History of active CHF or LVEF<50% at screening echocardiogram.
  • Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal medical therapy).
  • Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection.
  • Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. QOL, are allowed.
  • Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg po daily for thromboembolism prophylaxis is allowed).
  • Pregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
  • Patients may not have had previous treatment with a DTIC or temozolomide based chemotherapy regimen. In the Phase II part of the trial patients may not have had treatment with any chemotherapy regimen.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00496223
Other Study ID Numbers  ICMJE MCC-14743
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Adil Daud, M.D., UCSF (formerly at H. Lee Moffitt Cancer Center & Research Institute)
Study Sponsor  ICMJE H. Lee Moffitt Cancer Center and Research Institute
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Adil Daud, M.D.UCSF (formerly at H. Lee Moffitt Cancer Center & Research Institute)
PRS Account H. Lee Moffitt Cancer Center and Research Institute
Verification Date February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP